Enfusion, Inc. (NYSE:ENFN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Enfusion, Inc. (NYSE:ENFN) have earned a consensus recommendation of “Reduce” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.25.

A number of research analysts recently issued reports on the company. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday. Stifel Nicolaus boosted their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th.

Insiders Place Their Bets

In other news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 36.44% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Centiva Capital LP increased its stake in shares of Enfusion by 5.0% during the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Azora Capital LP increased its position in Enfusion by 6.8% during the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after buying an additional 1,890 shares in the last quarter. 272 Capital LP raised its stake in Enfusion by 1.5% during the second quarter. 272 Capital LP now owns 139,180 shares of the company’s stock valued at $1,186,000 after buying an additional 2,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after acquiring an additional 4,239 shares in the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Stock Up 0.6 %

Shares of Enfusion stock opened at $10.58 on Wednesday. The firm has a market cap of $1.36 billion, a PE ratio of 264.57, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97. The company’s fifty day simple moving average is $9.74 and its two-hundred day simple moving average is $9.02. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.38.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.